Low vitamin d status predicts poor clinical outcome in advanced melanoma treated with immune checkpoint or braf/mek inhibitors: a prospective non-interventional side-by-side analysis

HIGHLIGHTS

SUMMARY

Enormous scientific progress in molecular tumor biology and immune surveillance has resulted in the introduction of effective targeted therapies and immunotherapies for metastasized melanoma. An increasing number of clinical trials have impressively shown that BRAF inhibitors (BRAFi; such as dabrafenib, vemurafenib, and encorafenib), MEK inhibitors (MEKi; such as trametinib, cobimetinib, and binimetinib), and immune checkpoint inhibitors improve clinical outcomes when compared to chemotherapy. Inclusion criteria were treatment with CTLA-4i, PD-1i, or BRAFi/MEKi for histologically and clinically confirmed advanced melanoma [stages III and IV according to the 2009 edition of the American . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.